I'll research the DLL3 and ES-SCLC trial landscape to give you a grounded recommendation. Let me start by understanding what's in the database.
{
"indications": {
"ES-SCLC": {
"targets": [
"DLL3",
"PD-L1",
"SEZ6"
],
"n_trials": 7
},
"Gastric/GEJ": {
"targets": [
"CLDN18.2",
"PD-1"
],
"n_trials": 7
},
"HER2+ Breast": {
"targets": [
"HER2"
],
"n_trials": 5
},
"HER2-low Breast": {
"targets": [
"HER2"
],
"n_trials": 1
}
}
}Let me dig into the ES-SCLC landscape, focusing on DLL3 and the competing targets.
{
"count": 7,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
},
{
"nct": "NCT04471727",
"sponsor": "AbbVie",
"drug": "ABBV-011 (SC-002 / SEZ6 ADC)",
"indication": "ES-SCLC",
"target": "SEZ6",
"modality": "Antibody-drug conjugate",
"phase": "PHASE1",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 130,
"start_year": 2020,
"line": "2L+",
"primary_endpoint": "Safety / objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT03043872",
"sponsor": "Roche/Genentech",
"drug": "Atezolizumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 403,
"start_year": 2016,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03066778",
"sponsor": "AstraZeneca",
"drug": "Durvalumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 537,
"start_year": 2017,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}
]
}{
"count": 4,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
}
]
}Let me pull the detail on the key competitors — the Amgen Phase 3 (the pivotal incumbent) and the 1L standard-of-care trials that define the front-line landscape.
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}{
"nct": "NCT03066778",
"sponsor": "AstraZeneca",
"drug": "Durvalumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 537,
"start_year": 2017,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}{
"nct": "NCT04471727",
"sponsor": "AbbVie",
"drug": "ABBV-011 (SC-002 / SEZ6 ADC)",
"indication": "ES-SCLC",
"target": "SEZ6",
"modality": "Antibody-drug conjugate",
"phase": "PHASE1",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 130,
"start_year": 2020,
"line": "2L+",
"primary_endpoint": "Safety / objective response rate",
"control_arm": "Single arm"
}Let me also check whether Amgen has any earlier-line (1L maintenance/consolidation) tarlatamab programs in their broader pipeline, since that's a key strategic question.
{
"sponsor_query": "Amgen",
"count": 2,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
}
]
}{
"sponsor_query": "AstraZeneca",
"count": 3,
"trials": [
{
"nct": "NCT03066778",
"sponsor": "AstraZeneca",
"drug": "Durvalumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 537,
"start_year": 2017,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03529110",
"sponsor": "Daiichi Sankyo/AstraZeneca",
"drug": "Trastuzumab deruxtecan (T-DXd)",
"indication": "HER2+ Breast",
"target": "HER2",
"modality": "Antibody-drug conjugate",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 524,
"start_year": 2018,
"line": "2L",
"primary_endpoint": "Progression-free survival",
"control_arm": "T-DM1"
},
{
"nct": "NCT04494425",
"sponsor": "Daiichi Sankyo/AstraZeneca",
"drug": "Trastuzumab deruxtecan (T-DXd)",
"indication": "HER2-low Breast",
"target": "HER2",
"modality": "Antibody-drug conjugate",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 557,
"start_year": 2020,
"line": "2L+",
"primary_endpoint": "Progression-free survival",
"control_arm": "Chemotherapy"
}
]
}I now have a clear picture of the landscape. Here's my strategic read.
Front line (1L) is locked by chemo + checkpoint inhibitor (atezolizumab/IMpower133, durvalumab/CASPIAN). Both completed, both OS-positive — this is entrenched standard of care.
Second line and beyond (2L+) is where every targeted asset is crowded:
| Drug | Sponsor | Target | Modality | Phase | Line | Design |
|---|---|---|---|---|---|---|
| Tarlatamab | Amgen | DLL3 | BiTE | Ph3 (OS vs chemo) | 2L+ | The incumbent — defining the registrational bar |
| Obrixtamig (BI 764532) | Boehringer | DLL3 | BiTE | Ph2 | 2L+ | Single arm |
| LB2102 | Legend | DLL3 | CAR-T | Ph1 | 2L+ | Single arm |
| ABBV-011 | AbbVie | SEZ6 | ADC | Ph1 | 2L+ | Single arm |
The entire DLL3 field is concentrated in 2L+, and is dominated by T-cell engagers. Tarlatamab is already in a 600-pt Phase 3 with an OS endpoint vs chemo. Walking into 2L+ with a single-arm ORR study makes you the fourth DLL3 asset in the same setting and forces an inevitable head-to-head vs. an approved/near-approved BiTE.
You are an ADC, not a BiTE. Your only same-modality competitor (ABBV-011) is a different target (SEZ6) and only Phase 1. There is no DLL3 ADC in this database competing in ES-SCLC — that is your modality whitespace.
1L has no DLL3 presence at all. The front line is checkpoint+chemo with nothing targeting DLL3 — and the maintenance phase after induction is wide open.
Differentiate on line of therapy, not just target — go to the 1L maintenance/consolidation setting, and explicitly position the ADC mechanism as complementary to (not competitive with) the BiTEs.
Two concrete design paths:
Primary play — 1L maintenance after chemo-IO induction (highest differentiation):
- Design: chemo + checkpoint inhibitor induction → randomize maintenance to your DLL3 ADC + checkpoint inhibitor vs. checkpoint inhibitor alone (the current maintenance standard).
- Endpoint: PFS (registrational-feasible, faster readout) with OS as key secondary.
- Rationale: This is empty space. No DLL3 asset is here. An ADC's tolerability/dosing profile is far more compatible with chronic maintenance than a BiTE (no CRS/ICANS step-up dosing, no mandatory inpatient monitoring). That is a clean, defensible differentiation story that BiTE incumbents structurally cannot easily match.
Hedge/sequencing play — 2L+ but with a randomized OS design and biomarker enrichment:
- If you must start in relapsed disease for speed-to-clinic, do not repeat the single-arm ORR template that BI/Legend are running. Match tarlatamab's bar with a randomized OS design vs. chemo (lurbinectedin/topotecan), and enrich/stratify by DLL3 expression to carve a defined-population label.
- Critically, this also sets up a 2L+ population that is post-tarlatamab (BiTE-relapsed/refractory) — an ADC after a T-cell engager failure is a mechanistically distinct, clinically credible niche the incumbents leave open.
The losing move is 2L+ single-arm ORR — that puts you fourth in line behind a Phase 3 BiTE. The winning differentiation is 1L maintenance combination with a checkpoint inhibitor, leaning on the ADC's chronic-dosing tolerability advantage over BiTEs, with a fallback of a post-BiTE 2L+ randomized OS study if you need a faster, smaller proof-of-concept first.
One caveat: these recommendations are anchored to this database's 7 ES-SCLC trials. Before committing, I'd validate against the full competitive set (e.g., other DLL3 ADCs like ZL-1310/other sponsors, and any 1L tarlatamab maintenance studies Amgen may have started outside this dataset), since the 1L-maintenance whitespace is exactly where a well-funded incumbent would move next.
Want me to pull the full SEZ6 ADC (ABBV-011) record or any other competitor detail to pressure-test the combination/sequencing assumptions?
I now have a clear picture of the landscape. Here's my strategic read.
Front line (1L) is locked by chemo + checkpoint inhibitor (atezolizumab/IMpower133, durvalumab/CASPIAN). Both completed, both OS-positive — this is entrenched standard of care.
Second line and beyond (2L+) is where every targeted asset is crowded:
| Drug | Sponsor | Target | Modality | Phase | Line | Design |
|---|---|---|---|---|---|---|
| Tarlatamab | Amgen | DLL3 | BiTE | Ph3 (OS vs chemo) | 2L+ | The incumbent — defining the registrational bar |
| Obrixtamig (BI 764532) | Boehringer | DLL3 | BiTE | Ph2 | 2L+ | Single arm |
| LB2102 | Legend | DLL3 | CAR-T | Ph1 | 2L+ | Single arm |
| ABBV-011 | AbbVie | SEZ6 | ADC | Ph1 | 2L+ | Single arm |
The entire DLL3 field is concentrated in 2L+, and is dominated by T-cell engagers. Tarlatamab is already in a 600-pt Phase 3 with an OS endpoint vs chemo. Walking into 2L+ with a single-arm ORR study makes you the fourth DLL3 asset in the same setting and forces an inevitable head-to-head vs. an approved/near-approved BiTE.
You are an ADC, not a BiTE. Your only same-modality competitor (ABBV-011) is a different target (SEZ6) and only Phase 1. There is no DLL3 ADC in this database competing in ES-SCLC — that is your modality whitespace.
1L has no DLL3 presence at all. The front line is checkpoint+chemo with nothing targeting DLL3 — and the maintenance phase after induction is wide open.
Differentiate on line of therapy, not just target — go to the 1L maintenance/consolidation setting, and explicitly position the ADC mechanism as complementary to (not competitive with) the BiTEs.
Two concrete design paths:
Primary play — 1L maintenance after chemo-IO induction (highest differentiation):
- Design: chemo + checkpoint inhibitor induction → randomize maintenance to your DLL3 ADC + checkpoint inhibitor vs. checkpoint inhibitor alone (the current maintenance standard).
- Endpoint: PFS (registrational-feasible, faster readout) with OS as key secondary.
- Rationale: This is empty space. No DLL3 asset is here. An ADC's tolerability/dosing profile is far more compatible with chronic maintenance than a BiTE (no CRS/ICANS step-up dosing, no mandatory inpatient monitoring). That is a clean, defensible differentiation story that BiTE incumbents structurally cannot easily match.
Hedge/sequencing play — 2L+ but with a randomized OS design and biomarker enrichment:
- If you must start in relapsed disease for speed-to-clinic, do not repeat the single-arm ORR template that BI/Legend are running. Match tarlatamab's bar with a randomized OS design vs. chemo (lurbinectedin/topotecan), and enrich/stratify by DLL3 expression to carve a defined-population label.
- Critically, this also sets up a 2L+ population that is post-tarlatamab (BiTE-relapsed/refractory) — an ADC after a T-cell engager failure is a mechanistically distinct, clinically credible niche the incumbents leave open.
The losing move is 2L+ single-arm ORR — that puts you fourth in line behind a Phase 3 BiTE. The winning differentiation is 1L maintenance combination with a checkpoint inhibitor, leaning on the ADC's chronic-dosing tolerability advantage over BiTEs, with a fallback of a post-BiTE 2L+ randomized OS study if you need a faster, smaller proof-of-concept first.
One caveat: these recommendations are anchored to this database's 7 ES-SCLC trials. Before committing, I'd validate against the full competitive set (e.g., other DLL3 ADCs like ZL-1310/other sponsors, and any 1L tarlatamab maintenance studies Amgen may have started outside this dataset), since the 1L-maintenance whitespace is exactly where a well-funded incumbent would move next.
Want me to pull the full SEZ6 ADC (ABBV-011) record or any other competitor detail to pressure-test the combination/sequencing assumptions?
Deterministic summary over the curated trial set for the queried indication. A strong agent should recover the leaders, the phase/modality mix, and credible whitespace.
| Metric | Value | Note |
|---|---|---|
| Trials in scope | 7 | indication = ES-SCLC |
| By phase | PHASE1:2, PHASE2:2, PHASE3:3 | |
| By modality | T-cell engager (BiTE):3; Checkpoint inhibitor (mAb):2; CAR-T (autologous):1; Antibody-drug conjugate:1 | |
| Top sponsors | Amgen:2; Boehringer Ingelheim:1; Legend Biotech:1 | |
| Whitespace (modality @ line, no active trial) | Antibody-drug conjugate @ 1L; CAR-T (autologous) @ 1L; Checkpoint inhibitor (mAb) @ 1L; Checkpoint inhibitor (mAb) @ 2L+; T-cell engager (BiTE) @ 1L |